ライフサイエンスコーパス: bedaquiline

1 would likely result in greater resistance to bedaquiline.

2 assuming only patients with XDR TB received bedaquiline.

3 cal efficacy and the tolerability profile of bedaquiline.

4 agents moxifloxacin, PA-824, linezolid, and bedaquiline.

5 ude approval of two new drugs, delamanid and bedaquiline.

6 ) assuming all patients with MDR TB received bedaquiline, 35.1 y (34.4, 35.8) assuming patients with

7 eference MIC quality control (QC) ranges for bedaquiline, a diarylquinoline antimycobacterial, used i

8 d, our results provide support for expanding bedaquiline access to all patients with MDR TB.

9 he emergence of resistance to new therapies, bedaquiline and delamanid.

10 Moreover, verapamil reduced tolerance to bedaquiline and moxifloxacin.

11 Finally, because resistance to bedaquiline and other antituberculosis drugs is caused b

12 ations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine)

13 extensively drug-resistant (XDR) TB received bedaquiline, and 34.9 y (34.6, 35.2) assuming only patie

14 0% were likely to be sensitive to linezolid, bedaquiline, and delamanid.

15 ity rates of patients with XDR not receiving bedaquiline, and promising cohort study results, suggest

16 The explored strategies included making bedaquiline available to all patients with MDR TB, restr

17 linical evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an ex

18 t strategies for introducing the new TB drug bedaquiline based on patients' resistance patterns.

19 Bedaquiline (BDQ), a diarylquinoline antibiotic that tar

20 The use of bedaquiline combined with other active drugs has the pot

21 parameter sets, for parameter sets in which bedaquiline conferred high risks of added mortality and

22 and December 2015: ceftaroline, fidaxomicin, bedaquiline, dalbavancin, tedizolid, oritavancin, ceftol

23 ole of newer and repurposed drugs (including bedaquiline, delamanid, and linezolid), pharmacokinetic

24 >/=60-ms increase in QT interval, leading to bedaquiline discontinuation in 2 (6%) cases.

25 ch and provide guidance for routine clinical bedaquiline DST in laboratories worldwide.

26 Bedaquiline DST methodologies and MIC QC ranges against

27 Two tier-2 QC reproducibility studies of bedaquiline DST were conducted in eight laboratories usi

28 ong patients with MDR tuberculosis receiving bedaquiline for compassionate use between January 2010 a

29 ur position in favour of increased access to bedaquiline for these patients is based on three argumen

30 There were 10 deaths in the bedaquiline group and 2 in the placebo group, with no ca

31 sis, cure rates at 120 weeks were 58% in the bedaquiline group and 32% in the placebo group (P=0.003)

32 There were more deaths in the bedaquiline group than in the placebo group.

33 rom 125 days to 83 days (hazard ratio in the bedaquiline group, 2.44; 95% confidence interval, 1.57 t

34 bal rollout of the new antituberculosis drug bedaquiline has been slow, in part reflecting concerns a

35 within a single bacterial chromosome, use of bedaquiline in patients with XDR tuberculosis will not s

36 istance concerns should not forestall use of bedaquiline in patients with XDR tuberculosis.

37 h culture-positive pulmonary tuberculosis at bedaquiline initiation.

38 R plus additional resistance and withholding bedaquiline introduction completely.

39 Bedaquiline is a new antibiotic that was approved for th

40 ed contacts will face equivalent outcomes if bedaquiline is either not provided because of policy, or

41 Acquired resistance to bedaquiline is especially likely in patients with extens

42 Access to delamanid, bedaquiline, linezolid, and rifabutin, when appropriate,

43 Bedaquiline MIC frequency, mode, and geometric mean were

44 obiological equivalence was demonstrated for bedaquiline MICs determined using 7H10 agar and 7H11 aga

45 ed using 7H10 agar and 7H11 agar but not for bedaquiline MICs determined using 7H9 broth and 7H10 aga

46 .1% (207/211, with one data set excluded) of bedaquiline MICs.

47 d) or 95.9% (7H11 agar dilution; 232/242) of bedaquiline MICs.

48 t, the use of drug combinations that include bedaquiline might prevent spread of XDR disease to other

49 ant tuberculosis to receive either 400 mg of bedaquiline once daily for 2 weeks, followed by 200 mg t

50 e determine the effect of the ETC inhibitors bedaquiline, Q203 and clofazimine on the Mtb ETC, and th

51 Bedaquiline reduced the median time to culture conversio

52 trategies consistently increased the risk of bedaquiline resistance but decreased the risk of resista

53 will not substantially increase the risk of bedaquiline resistance in patients with drug-susceptible

54 in part reflecting concerns about spread of bedaquiline resistance.

55 Absence of cross resistance against bedaquiline resistant mutants suggested a different bind

56 Bedaquiline shows potential for the treatment of M. intr

57 Bedaquiline (Sirturo, TMC207), a diarylquinoline that in

58 With a particular focus on bedaquiline (TMC207), the first anti-TB drug of a novel

59 mycin, amikacin, cefoxitin, tigecycline, and bedaquiline (TMC207).

60 The addition of bedaquiline to a preferred background regimen for 24 wee

61 Although providing bedaquiline to all MDR patients resulted in the highest

62 The approval of bedaquiline to treat tuberculosis has validated adenosin

63 At 6 months of bedaquiline treatment, culture conversion was achieved i

64 0 and July 2013 and evaluated at 6 months of bedaquiline treatment.

65 ble to all patients with MDR TB, restricting bedaquiline usage to patients with MDR plus additional r

66 Across all parameter sets, the most liberal bedaquiline use strategies consistently increased the ri

67 In almost all cases, more liberal bedaquiline use strategies reduced the expected number o

68 -resistant (MDR) TB patients under different bedaquiline use strategies.

69 line displayed bactericidal activity whereas bedaquiline was almost inactive.

70 Bedaquiline was associated with a median of 4 (range, 2-